Home » Stocks » GSK

GlaxoSmithKline plc (GSK)

Stock Price: $38.47 USD 0.00 (0.00%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $38.51 +0.04 (0.10%) Jan 15, 7:51 PM
Market Cap 97.28B
Revenue (ttm) 44.41B
Net Income (ttm) 6.11B
Shares Out 5.38B
EPS (ttm) 0.99
PE Ratio 38.78
Forward PE 11.85
Dividend $2.03
Dividend Yield 5.28%
Trading Day January 15
Last Price $38.47
Previous Close $38.47
Change ($) 0.00
Change (%) 0.00%
Day's Open 38.38
Day's Range 38.21 - 38.66
Day's Volume 3,100,857
52-Week Range 31.08 - 46.66

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 5 days ago

Vir Biotechnology (VIR) and its British partner, Glaxo announces agreement umder which they will evaluate their second coronavirus therapeutic candidate.

PRNewsWire - 1 week ago

PARIS, Jan. 11, 2021 /PRNewswire/ -- Eligo Bioscience SA (Eligo) today announced that it has entered into a research and option agreement with GlaxoSmithKline (NYSE: GSK) aimed at advancing El...

Seeking Alpha - 2 weeks ago

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Other stocks mentioned: BIIB, BK, BTI, IMBBY, INTC, LMT, MO, MRK, RHHBY, SNY
InvestorPlace - 2 weeks ago

As the Covid-19 pandemic worsens, the case for dental stocks to buy might not seem too bright. However, this sector is a very broad one, with upside opportunities available right now.

Other stocks mentioned: CL, CVS, HSIC, JNJ, MMM, PG, XRAY
The Motley Fool - 3 weeks ago

Hopefully, the backup plan works.

Other stocks mentioned: SNY
Benzinga - 4 weeks ago

British pharmaceutical company GlaxoSmithKline PLC's (NYSE: GSK) majority-owned subsidiary ViiV Healthcare received the marketing authorization approval for its HIV treatment in the European U...

PRNewsWire - 4 weeks ago

TOKYO and CAMBRIDGE, England, Dec. 21, 2020 /PRNewswire/ -- Sosei Group Corporation ("the Company") (TSE: 4565) announces it has entered into a global collaboration and license agreement with ...

Zacks Investment Research - 1 month ago

In the latest trading session, GlaxoSmithKline (GSK) closed at $37.01, marking a -0.88% move from the previous day.

Market Watch - 1 month ago

Shares of Vir Biotechnology Inc. gained 1.3% in premarket trading on Friday, the day after the biotech and GlaxoSmithKline said they started dosing patients in a late-stage clinical trial for ...

Other stocks mentioned: VIR
PRNewsWire - 1 month ago

LONDON, Dec. 17, 2020 /PRNewswire/ -- GlaxoSmithKline plc (LSE/NYSE: GSK) announced the US Food and Drug Administration (FDA) has approved BENLYSTA (belimumab) for the treatment of adult patie...

Zacks Investment Research - 1 month ago

Glaxo (GSK) receives positive opinion from the Committee for Medicinal Products for Human Use, recommending approval of Rukobia for treating HIV-1 infection in heavily pre-treated adult HIV pa...

The Motley Fool - 1 month ago

The vaccine giants will be rethinking the formulation of their coronavirus candidate before a new phase 2 study.

Other stocks mentioned: SNY
Zacks Investment Research - 1 month ago

Glaxo (GSK)/Sanofi's (SNY) adjuvanted recombinant COVID-19 vaccine candidate shows low immune response in older adults in phase I/II study. The companies will develop the vaccine with an impro...

Other stocks mentioned: SNY
New York Post - 1 month ago

Sanofi and GlaxoSmithKline pushed back the timeline for rolling out their coronavirus vaccine after finding it didn't work as well in older people. The drugmakers' Friday announcement created ...

Other stocks mentioned: SNY
Market Watch - 1 month ago

Sanofi and GlaxoSmithKline, the French and British pharmaceutical groups, said on Friday that they would delay the launch of their joint coronavirus vaccine until the end of 2021.

Other stocks mentioned: SNY
Forbes - 1 month ago

The vaccine will not be available until the last quarter of 2021.

Other stocks mentioned: SNY
CNBC International TV - 1 month ago

Covid vaccine by Sanofi-GSK delayed after disappointing results in older patients

CNBC's Charlotte Reed reports on the setback suffered by Sanofi and GSK in the development of their Covid-19 vaccine, now not expected until the latter part of 2021.

Other stocks mentioned: SNY
Business Insider - 1 month ago

A COVID-19 vaccine being developed by two of the world's biggest vaccine makers, GlaxoSmithKline and Sanofi, has been delayed after it didn't show a strong enough response in older people. Gla...

Other stocks mentioned: SNY
Reuters - 1 month ago

GlaxoSmithKline said on Friday its goal to produce 1 billion doses of adjuvants - designed to boost COVID-19 vaccine efficacy - in 2021 remained in place but was under review following a devel...

Reuters - 1 month ago

Sanofi and GlaxoSmithKline said clinical trials of their COVID-19 vaccine showed an insufficient immune response in older people, delaying its launch to late next year and marking a setback in...

Other stocks mentioned: SNY
Benzinga - 1 month ago

Sanofi SA (NASDAQ: SNY) and GlaxoSmithKline plc (NYSE: GSK) on Friday reported a delay in their COVID-19 vaccine program as interim results from Phase 1 and 2 trials indicate a low immune resp...

Other stocks mentioned: SNY
Seeking Alpha - 1 month ago

IDEAYA Biosciences is an oncology specialist focused on precision medicine aiming to utilize molecular diagnostics to develop targeted therapeutics with a research focus on synthetic lethality.

GlobeNewsWire - 1 month ago

Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly

Other stocks mentioned: SNY
Zacks Investment Research - 1 month ago

In the latest trading session, GlaxoSmithKline (GSK) closed at $37.97, marking a +0.34% move from the previous day.

Zacks Investment Research - 1 month ago

The FDA accepts Glaxo's (GSK) regulatory filing for Nucala to treat patients with chronic rhinosinusitis with nasal polyps. The drug is already approved for three other indications.

InvestorPlace - 1 month ago

Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021. The post The 7 Best Coronavirus Vaccine Stocks Still In The Ra...

Other stocks mentioned: AZN, BIIB, BNTX, MRNA, PFE, SNY
Seeking Alpha - 1 month ago

The largest pharmaceutical companies in the world are restructuring.  Biopharma represents a far more valuable future than growth-dilutive consumer health revenues. GSK cleared room for next g...

The Motley Fool - 1 month ago

These three could deliver big for investors once their vaccines are approved for sale.

Other stocks mentioned: JNJ, NVAX
Market Watch - 1 month ago

GlaxoSmithKline was downgraded to neutral from buy at UBS, which said the European pharma sector is cheap -- trading at a double-digit discount to the market on forward price-to-earnings -- bu...

PRNewsWire - 1 month ago

WARREN, N.J., Dec. 1, 2020 /PRNewswire/ -- GlaxoSmithKline (LSE/NYSE: GSK) today announced a donation of $1 million to Direct Relief on behalf of consumers who have purchased its consumer heal...

Seeking Alpha - 1 month ago

Our three-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison.

Other stocks mentioned: BAYRY, BIIB, BTI, IMBBY, INTC, LMT, MO, MRK, PM, RHHBY, SNY
Seeking Alpha - 1 month ago

Sum-of-parts analysis reveals that GSK is significantly undervalued and its true value is likely to be unlocked by its consumer healthcare JV and subsequent spin-off. The strategy aligns well ...

Seeking Alpha - 1 month ago

GlaxoSmithKline remains a high-yield pick in pharma, partially a consequence of several years of little growth and portfolio attrition to generics. Recent waves of drugs falling off-patent lea...

Zacks Investment Research - 1 month ago

Glaxo (GSK) is developing vaccine against respiratory syncytial virus for pediatric patients, pregnant women and older adults. The candidates hold significant potential.

The Motley Fool - 1 month ago

Dr. Angela Rasmussen explains what investors should know about an under-the-radar coronavirus vaccine developer.

Zacks Investment Research - 1 month ago

Let's see if GlaxoSmithKline (GSK) stock is a good choice for value-oriented investors right now from multiple angles.

Business Wire - 1 month ago

Largest first-time venture capital fund to close in 2020 focused on US/EU biotech

The Motley Fool - 1 month ago

Dr. Angela Rasmussen explains why news from mRNA vaccine trials is so promising and shares tips for investors thinking about buying stocks like Pfizer and Moderna.

Other stocks mentioned: AZN, BNTX, JNJ, MRNA, NVAX, PFE, SNY
Zacks Investment Research - 2 months ago

FDA grants breakthrough designation to Glaxo's (GSK) long-acting injectable cabotegravir to decrease the risk of HIV acquisition in at-risk populations.

The Motley Fool - 2 months ago

With immobile stock prices and a hangover of legal issues, these CEOs might be glad Wall Street doesn't operate like a democracy.

Other stocks mentioned: BAYRY
Insider Monkey - 2 months ago

In this article we present the list of 10 Best Dividend Stocks To Buy According To Billionaire Ken Fisher. Click to skip ahead and see the  5 Best Dividend Stocks To Buy According To Billionai...

Other stocks mentioned: BBL, BHP, COP, CVX, RDS.A, RDS.B, RIO, TOT, VALE, XOM
GeekWire - 2 months ago

Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19.

Other stocks mentioned: ADPT
Seeking Alpha - 2 months ago

GSK and ABBV are both attractively valued and high-yield picks available in the pharma space, discounted for their respective generics-eroded segments. We think that neither is a bad option in...

Other stocks mentioned: ABBV
GuruFocus - 2 months ago

Kahn Brothers (Trades, Portfolio) has released its third-quarter portfolio. Throughout the portfolio holdings were reduced or sold completely, with the largest changes coming from Merck & Co. ...

Other stocks mentioned: BMY, C, MRK, SEB
Seeking Alpha - 2 months ago

We selected 9 defensive Dividends Aristocrats from 9 Sectors with average dividend yield of 6.7%, including several yielding more than 9%. The stocks in our selection have relatively low corre...

Other stocks mentioned: ABB, IBM, IRM, KHC, PRU, RIO, T, TOT
The Motley Fool - 2 months ago

The European Commission has joined the Food and Drug Administration in accepting Zejula as a front-line therapy.

Zacks Investment Research - 2 months ago

Glaxo (GSK) witnesses recovery in vaccinations rates in the third quarter. Performance of Pharmaceuticals and Consumer Healthcare businesses improve.

Seeking Alpha - 2 months ago

GlaxoSmithKline PLC (GSK) CEO Emma Walmsley on Q3 2020 Results - Earnings Call Transcript

New York Post - 2 months ago

Sanofi and GlaxoSmithKline have committed 200 million doses of their experimental coronavirus vaccine to a global effort to distribute shots around the world, the drugmakers said Wednesday. Th...

Other stocks mentioned: SNY
Forbes - 2 months ago

The companies hope to apply for approval in the first half of 2021.

Other stocks mentioned: SNY

About GSK

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous syste... [Read more...]

Industry
Drug Manufacturers-General
Founded
1715
CEO
Emma Walmsley
Employees
99,437
Stock Exchange
NYSE
Ticker Symbol
GSK
Full Company Profile

Financial Performance

In 2019, GSK's revenue was 33.75 billion, an increase of 9.52% compared to the previous year's 30.82 billion. Earnings were 4.65 billion, an increase of 28.21%.

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for GSK stock is "Buy." The 12-month stock price forecast is 48.50, which is an increase of 26.07% from the latest price.

Price Target
$48.50
(26.07% upside)
Analyst Consensus: Buy